|Bid||180.55 x 1100|
|Ask||181.55 x 1100|
|Day's Range||177.71 - 182.70|
|52 Week Range||176.36 - 242.99|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||17.23|
|Earnings Date||Oct 27, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||258.59|
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has announced Day 90 data for the first patient from the Phase 1/2 trial of VX-880 for type 1 diabetes (T1D). VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy. The patient, who had suffered five potentially life-threatening hypoglycemic (low blood sugar) episodes in the year before the therapy, was injected with synthetic insulin-producing cells. After 90 days, the patient’s new cells
BOSTON, October 18, 2021--Vertex today announced positive data for the first patient from the Phase 1/2 clinical trial of VX-880, for the treatment of type-1 diabetes.
Following the quickest decline of at least 30% in the S&P 500's storied history during the first quarter of 2020, the benchmark index took less than 17 months from hitting its trough to double in value. As long as your investing time frame is measured in years and not days or weeks, there are plenty of great companies at attractive valuations that can be purchased right now. To start with the obvious, bank stocks are inherently cyclical.